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AIM
Di!erent studies evaluated the role of ADAR1 in di!erent kinds of cancer, 
for which increasing of ADAR1 expression is linked to a worst prognosis and 
metastasis. Unclear results came from one study published about ADAR1 in 
oral squamous cell carcinoma (OSCC)1. Aim of our study was to perform a 
histologic analysis by immunohistochemistry in order to deeply evaluate the 
role of ADAR1 in OSCC patients. 
MATERIALS AND METHODS
For the analysis of ADAR1 expression, we used a tissue microarray (TMA) 
including 54 patients, who filled informed consent. The source para"n blocks 
were cored. A rabbit monoclonal antibody (Ab) supplied by abcam code 
[EPR7033] (ab126745), was used to perform the immuno-histochemical stain-
ing. Observational quantification analysis was performed by an experienced 
pathologist, according to two parameters: the intensity of staining and the 
percentage of the stained cells in both cytoplasm and nucleus. The intensity 
(I) of expression was scored from 0 to 3 (0 = no staining; 1 = yellow; 2=light 
brown; 3 = black brown/black). The proportion (%) of cells staining positively 
was scored from 1 to 6 (1 = 0-4%; 2 = 5-19%; 3 = 20-39%; 4 = 40-59%; 5 = 
60-79%; 6 = 80-100%). Categorization of the scores in low (0-1/0-1-2-3) and 
high (2-3/4-5-6) intensity/percentage of positive expression for ADAR1, was 
undertaken in order to highlight a possible and di!erent role of ADAR1 accord-
ing to its allocation. SPSS 21.0 Software was used for the statistical analysis. 
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RESULTS
Multivariate Cox regression analysis explored how ADAR1 with di!erent pat-
tern of expression, in both nucleus or cytoplasm, could influence the patients’ 
relapse and prognosis. Relapse-Free Survival (RFS) and Overall Survival (OS) 
were analyzed. Here were report only statically significant results. At Univariate 
analysis of Kaplan-Meier, lower percentage of stained nuclei, resulted to 
influence the recurrence status (p = 0,012). Lower number of nuclei stained 
resulted to be linked to an increase of appearance of relapses. We think this 
result should be analyzed farther in a bigger sample size, first of all, because 
in our cohort, there were not registered many relapse events. In the second 
place, Multivariate analysis failed to find this association. According to the 
OS, surprising results came from both Univariate and Multivariate analysis. 
ADAR1 resulted to be an independent prognostic factor when expressed in 
the cytoplasm. In particular from Kaplan-Meier analysis, the higher intensity of 
ADAR1 expression in the cytosol seems to be a favorable prognostic factor for 
the survival (p = 0,020). The higher number of stained cells in the cytoplasm, 
anyway, failed to find this association (p = 0,078). At multivariate analysis pre-
vious results were confirmed. ADAR1 resulted to be an independent protective 
prognostic factor in OSCC, when higher expressed (p = 0,003; Hazard Ratio 
0,100; 95% C.I. 0,022-0,450). By this analysis, also Grade and Stage resulted 
to be independent prognostic factor, with a worst prognosis. Higher grade 
resulted to influence with an HR of 3,381, C.I. 1,116-10,239; p = 0,031. HR for 
Staging resulted to be 2,328; C.I. 1,157-4,684; p = 0,018.
DISCUSSION
It is reported that the most common type of cancer in men in south-central 
Asia is OSCC, with more than 200.000 new cases per year in the world. Even 
if treatment modalities got a great improve in the last years, 5-years survival 
rate for this disease, didn’t improve as well, being below 50%. Thanks to an 
increase knowledge of tumor biology and technologies, we are able to better 
understand the events that could a!ect the normal cell in its change to a 
cancer cell. It’s well known that accumulation of mutations it’s an important 
mechanism, leading to a genetic change in the normal sequence of normal 
cell DNA. Anyway, these events are most in the cases supported by other 
mechanisms, which take the name of epigenetic and post-transcriptional 
events. In this view, one well-known epigenetic phenomenon is the 
RNA-editing. One of main character in this event is the ADAR1 enzyme, 
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which catalyzes a RNA change by modifying an adenosine to an inosine 
in the reading sequence. ADAR1, with two other isoforms, ADAR2 and 
ADAR2, belongs to the ADAR family. ADAR1 locus is on human chromosome 
1q21.1-q21.2, made of 15 exons for a total of around 30 KBs. Its transcripts are 
generated and allocated in cytoplasm or nucleus. The reaction catalyzed is a 
deamination of adenosine to inosine, which is read as guanosine. Thus, the 
editing event is considered as an A-to-G “mutation” in the target RNA, with 
consequence in the transcription process and in the final protein structure. 
In many cancers ADAR1 resulted to be amplificated. In vitro experiments 
reported that upregulation of ADAR1 brought to an increase of cancerous 
characteristics in cells, such as proliferation and migration. The link between 
ADAR1 and this change in phenotype is still unclear, but the answer could be 
in the RNA-editing events that this enzyme could determinate. It is reported 
that in one case, in an experimental in vitro study of melanoma cells, ADAR1 
resulted to be downregulated, but still linked to a malignant phenotype2,3. 
We firstly report, above all in OSCC, that ADAR1 increased expression in the 
cytoplasm is protective and influence the patients’ prognosis. This result is 
against a previous study, which investigate the role of ADAR1 in OSCC patients. 
First, di!erences could be seen in the antibody used. That research team used 
a polyclonal antibody; meanwhile we choose a monoclonal one. This could 
explain the di!erence in binding the specific target, with a di!erent signal in 
staining. They also did not perform a univariate or multivariate analysis on their 
sample. This could justify the di!erence in outcome. Also scoring system is 
substantially di!erent: a di!erential expression pattern between nucleus of 
cytoplasm is not clear in that study. In conclusion, bigger sample sized study 
are needed, with a standardized scoring method. This would help in a better 
understanding of ADAR1 role in OSCC patients and prognosis. This clinical 
study should be integrated with bio-molecular studies. This kind of studies 
could help to clarify the role of ADAR1 in the di!erent events that characterized 
cancer. What is sure, that ADAR1 could have di!erent behavior according to 
the cancer type and above all its localization, according to which substrates 
are present in the cell. This relation, then, could influence the prognosis. 
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